18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response

被引：233

作者：

Ben-Haim, Simona ^{[1
]}

Ell, Peter ^{[1
]}

机构：

[1] UCL, Inst Nucl Med, London, England

来源：

JOURNAL OF NUCLEAR MEDICINE | 2009年 / 50卷 / 01期

关键词：

F-18-FDG; PET; PET/CT; tumor response; treatment monitoring; outcome; POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKINS-LYMPHOMA; CELL LUNG-CANCER; PRIMARY BREAST-CANCER; FDG-PET; THERAPY RESPONSE; PROGNOSTIC VALUE; RECTAL-CANCER; NEOADJUVANT CHEMOTHERAPY; PATHOLOGICAL RESPONSE;

D O I：

10.2967/jnumed.108.054205

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in the evaluation of a patient presenting with cancer. With F-18-FDG, PET/CT is rapidly becoming the key investigative tool for the staging and assessment of cancer recurrence. In the last 5 y, PET/CT has also gained widespread acceptance as a key tool used to demonstrate early response to intervention and therapy. In this setting, a major clinical need is being addressed with F-18-FDG PET/CT, because of its inherent ability to demonstrate (before other markers of response) if disease modification has occurred. This review presents available evidence to this effect.

引用

收藏

页码：88 / 99

页数：12

相关论文

共 81 条

[1] Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer:: correlation with endorectal ultrasound and histopathology [J].

Amthauer, H ;

Denecke, T ;

Rau, B ;

Hildebrandt, B ;

Hünerbein, M ;

Ruf, J ;

Schneider, U ;

Gutberlet, M ;

Schlag, PM ;

Felix, R ;

Wust, P .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (06) :811-819

[2]

Antoch G, 2004, J NUCL MED, V45, P357

[3] The changing classification of non-Hodgkin's lymphomas [J].

Armitage, JO .

CA-A CANCER JOURNAL FOR CLINICIANS, 1997, 47 (06) :323-&

[4]

Aspinall MG, 2007, HARVARD BUS REV, V85, P108

[5] Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer [J].

Avril, N ;

Sassen, S ;

Schmalfeldt, B ;

Naehrig, J ;

Rutke, S ;

Weber, WA ;

Werner, M ;

Graeff, H ;

Schwaiger, M ;

Kuhn, W .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7445-7453

[6] F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging [J].

Avril, Norbert ;

Adler, Lee P. .

RADIOLOGIC CLINICS OF NORTH AMERICA, 2007, 45 (04) :645-+

[7] We should desist using RECIST, at least in GIST [J].

Benjamin, Robert S. ;

Choi, Haesun ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Charnsangavej, Chuslip .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1760-1764

[8] Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas:: Interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors [J].

Benz, Matthias R. ;

Evilevitch, Vladimir ;

Allen-Auerbach, Martin S. ;

Eilber, Fritz C. ;

Phelps, Michael E. ;

Czernin, Johannes ;

Weber, Wolfgang A. .

JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (07) :1038-1046

[9] [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy [J].

Berriolo-Riedinger, Alina ;

Touzery, Claude ;

Riedinger, Jean-Marc ;

Toubeau, Michel ;

Coudert, Bruno ;

Arnould, Laurent ;

Boichot, Christophe ;

Cochet, Alexandre ;

Fumoleau, Pierre ;

Brunotte, Francois .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (12) :1915-1924

[10] FDG-PET in monitoring therapy of breast cancer [J].

Biersack, HJ ;

Bender, H ;

Palmedo, H .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (Suppl 1) :S112-S117

← 1 2 3 4 5 6 7 8 9 →